Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4178859 | 0.82 | GAA (1.00) | KDM4EGAAMAPTALDH1A1MAPK1 | |
| SCHEMBL3632896 | 0.80 | KDM4E (0.63) | KDM4EGAAMAPTALDH1A1MAPK1 | |
| SCHEMBL2851246 | 0.78 | MAPT (1.00) | KDM4EGAAMAPTALDH1A1MAPK1 | |
| SCHEMBL4177085 | 0.76 | MAPT (0.71) | KDM4EGAAMAPTALDH1A1MAPK1 | |
| SCHEMBL11887684 | 0.75 | GAA (1.00) | KDM4EGAAMAPTALDH1A1MAPK1 | |
| SCHEMBL28406046 | 0.74 | MAPT (0.60) | KDM4EMAPTALDH1A1MAPK1LMNA | |
| SCHEMBL29890207 | 0.74 | MAPT (0.60) | KDM4EMAPTALDH1A1MAPK1LMNA | |
| SCHEMBL4178625 | 0.73 | GAA (0.65) | KDM4EGAAMAPTALDH1A1MAPK1 | |
| SCHEMBL15020489 | 0.72 | MAPT (0.66) | KDM4EGAAMAPTALDH1A1MAPK1 | |
| SCHEMBL5917995 | 0.71 | KDM4E (0.55) | KDM4EGAAMAPTALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963455-B2 | Pyrazolo[1,5-a]pyrimidines as antiviral compounds | CUROVIR AB (SE) | 2018-05-08 | — | — | US | disclosed |
| US-9963455-B2 | Pyrazolo[1,5-a]pyrimidines as antiviral compounds | CUROVIR AB (SE) | 2018-05-08 | — | — | US | disclosed |
| US-20160318937-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL COMPOUNDS | CUROVIR AB (SE) | 2016-11-03 | — | — | US | disclosed |
| US-20160318937-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL COMPOUNDS | CUROVIR AB (SE) | 2016-11-03 | — | — | US | disclosed |
| WO-2015110491-A2 | PYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE DERIVATIVES USEFUL IN THERAPY | APODEMUS AB (SE) | 2015-07-30 | — | — | WO | disclosed |
| EP-2081933-B1 | PYRAZOLOPYRIMIDINES AS PI3K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-23 | — | — | EP | disclosed |
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | CAPRARO HANS-GEORG | 2010-12-09 | — | — | US | disclosed |
| CN-101678026-A | 3, 6-disubstituted-imidazo [1, 2-B] pyridazines and 3, 5-disubstituted pyrazolo[1, 5-A] pyrimidines as phosphatidylinositol-3-kinase inhibitors | NOVARTIS AG | 2010-03-24 | — | — | CN | disclosed |
| US-20100069395-A1 | Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid compounds as protein kinase inhibitors | IMBACH PATRICIA | 2010-03-18 | — | — | US | disclosed |
| EP-2155202-A2 | 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AND 3,5-DISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| CN-101228167-A | Pyrazolo [1, 5-A ] pyrimidin-7-yl-amine derivatives as protein kinase inhibitors | NOVARTIS AG (CH) | 2008-07-23 | — | — | CN | disclosed |
| WO-2008052964-A1 | 3-AMINOCARBONYI-SUBSTITUTED FUSED PYRAZOLO-DERIVATIVES AS PROTEIN KINASE MODULATORS | NOVARTIS AG (CH) | 2008-05-08 | — | — | WO | disclosed |
| EP-1918291-A1 | 3-Aminocarbonyl-substituted fused pyrazolo-derivatives as protein kinase modulators | Novartis AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2008037477-A1 | PYRAZOLOPYRIMIDINES AS P13K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008037477-A1 | PYRAZOLOPYRIMIDINES AS P13K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-04-03 | — | — | WO | disclosed |
| WO-2007103432-A9 | USE OF PYRAZOLO[1,5A]PYRIMIDIN-7-YL AMINE DERIVATIVES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2008-01-10 | — | — | WO | disclosed |
| WO-2007103432-A2 | USE OF PYRAZOLO[1,5A]PYRIMIDIN-7-YL AMINE DERIVATIVES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2007-09-13 | — | — | WO | disclosed |
| EP-1708710-A1 | PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| US-20050222171-A1 | Organic compounds | NOVARTIS AG (CH) | 2005-10-06 | — | — | US | disclosed |
| WO-2005070431-A1 | PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318937-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL COMPOUNDS | TYMP, ZC3HAV1, TYMS | KDM4E 3727/4885GAA 666/4885MAPT 2846/4885 |
| US-20100069395-A1 | Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid compounds as protein kinase inhibitors | PRKCA, PRKACA, MAP3K19 | KDM4E 2751/4885GAA 1902/4885MAPT 2946/4885 |
| US-20050222171-A1 | Organic compounds | JAK1, MAP3K5, MAP3K7 | KDM4E 1049/4885GAA 651/4885MAPT 793/4885 |
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | PI4KA, PIP5K1B, PIP4K2A | KDM4E 2784/4885GAA 2032/4885MAPT 4070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.